This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III triple-negative breast cancer with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.
Wondering if you qualify as a candidate for this trial? Visit the "View Trial" button below and print the the trial's details to discuss with your Cancer Care Northwest physician.
For More Information
If you're interested in participating in this clinical trial, please complete the form below. A member of the Cancer Care Northwest Clinical Research Department will review your information and contact you shortly.
